ImpediMed Limited (ASX:IPD)

Market Cap	16.37M -79.3%
Revenue (ttm)	14.23M +23.3%
Net Income	-24.37M
EPS	-0.01
Shares Out	2.34B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,680,077
Average Volume	8,351,367
Open	0.0080
Previous Close	0.0080
Day's Range	0.0070 - 0.0080
52-Week Range	0.0070 - 0.0590
Beta	1.21
RSI	32.52
Earnings Date	May 1, 2026

About ImpediMed

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 77
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IPD

Financial Performance

In fiscal year 2025, ImpediMed's revenue was 12.72 million, an increase of 23.31% compared to the previous year's 10.32 million. Losses were -23.24 million, 17.4% more than in 2024.